Wegovy Side Effects in Women: What to Expect and How to Manage Them

Starting Wegovy is a significant decision. The medication works, the clinical evidence is clear, and for many women it genuinely changes their relationship with food. But it comes with a side effect profile that varies from person to person, and there are aspects of that profile that are specific to women: menstrual changes, hormonal interactions, and considerations around fertility.

This article covers the full side effect landscape for women on Wegovy, with data from the STEP 1 trial and practical management strategies for every stage of treatment.

The Core Side Effect Data: What STEP 1 Actually Found

The STEP 1 trial is the landmark randomised controlled trial that underpins Wegovy's approval for obesity treatment. It enrolled 1,961 adults and ran for 68 weeks, which means it gives us solid data on both early and ongoing side effects.

The gastrointestinal effects dominate the early months:

• Nausea: 44% of participants experienced nausea on semaglutide versus 16% on placebo
• Diarrhoea: 30% versus 16% on placebo
• Vomiting: 24% versus 6% on placebo
• Constipation: 24% versus 11% on placebo
• Abdominal pain: 20% versus 13% on placebo

These figures look alarming on paper. What they don't capture is the trajectory: the vast majority of GI side effects peak in the first 4-8 weeks and then decrease substantially. By week 12-20, most participants who remained on the medication reported either no GI symptoms or symptoms they rated as mild and manageable.

The reason side effects concentrate in the dose escalation period is pharmacological. Semaglutide slows gastric emptying. When the dose increases, the gut has to adapt to a new level of receptor activation. Each dose step triggers an adaptation period; once the body adjusts, symptoms typically reduce.

The Dose Escalation Schedule: Why It Matters

Wegovy's dose escalation is designed specifically to minimise side effects. You do not start at the full therapeutic dose:

| Weeks | Dose | |-------|------| | 1-4 | 0.25 mg weekly | | 5-8 | 0.5 mg weekly | | 9-12 | 1.0 mg weekly | | 13-16 | 1.7 mg weekly | | 17+ | 2.4 mg weekly (maintenance) |

Each step up carries a risk of transient nausea or GI disturbance. If side effects at any dose are severe enough to significantly impair daily life, clinicians can pause at the current dose for an additional 4 weeks before stepping up. This is not failure. It is appropriate titration.

The worst week for most people is typically the first week at each new dose, with symptoms subsiding by week 2-3 at that level. The step from 1.7 mg to 2.4 mg is often the most difficult, as it's the largest absolute increase.

Managing GI Side Effects

Nausea: The Main Event

Nausea is the side effect most women contact their clinic about. The good news is that it responds well to specific dietary interventions.

Foods that minimise nausea:

• Plain, dry foods at the start of the day: plain crackers, plain rice cakes, dry toast
• Ginger (as tea, crystallised ginger, or ginger biscuits) has modest clinical evidence for nausea reduction
• Cold or room-temperature foods, which have less aroma than hot food
• Small portions every 3-4 hours rather than full meals
• Protein sources that stay tolerable when nausea is present: plain boiled eggs, low-fat Greek yoghurt, cottage cheese, plain white fish

Foods and habits that worsen nausea:

• Fatty, greasy, or fried food (slows gastric emptying further when the medication is already slowing it)
• Spicy food
• Large meals. The stomach capacity on Wegovy is effectively reduced; eating past comfortable fullness triggers nausea reliably
• Eating too quickly. Put the fork down between bites. Slow eating gives the gut time to signal fullness before overflow occurs
• Lying down immediately after eating

Hydration: Nausea and reduced eating can lead to inadequate fluid intake. Aim for 2-2.5 litres of fluid per day. If solid food is difficult, clear broths, diluted juice, and oral rehydration sachets are useful short-term bridges.

For the full dietary strategy during GLP-1 treatment, see what to eat on a GLP-1 in the UK.

Constipation

Constipation is reported by around 24% of STEP 1 participants and can be persistent if not actively managed. Because semaglutide slows gastric motility, the colon receives food more slowly, and transit time increases.

Practical interventions:

• Gradually increase dietary fibre to 25-30 g/day (but do this incrementally to avoid bloating, which can worsen nausea)
• Adequate fluid intake is essential; fibre without water makes constipation worse
• Movement helps. Even a 20-minute walk each day significantly improves gut transit
• If dietary measures are insufficient, osmotic laxatives such as macrogol (Movicol) are safe alongside Wegovy. Avoid stimulant laxatives as a first response

Diarrhoea

Diarrhoea tends to be more episodic than constipation and often occurs at dose escalation steps. The practical approach:

• Temporarily reduce dietary fat for 2-3 days at each dose step
• Stay well hydrated, as diarrhoea increases fluid and electrolyte loss
• Consider electrolyte supplementation if diarrhoea is frequent; see electrolytes on semaglutide
• Diarrhoea that persists beyond 2 weeks at a stable dose warrants a call to your prescribing clinic

Women-Specific Effects

Menstrual Cycle Changes

This is the aspect of Wegovy's side effect profile that is least well-documented and most commonly surprises women.

Menstrual changes during Wegovy treatment are reported by a meaningful number of women, including cycle length changes, heavier or lighter periods, and in some cases temporary disruption to cycle regularity. The mechanism is not fully established, but there are plausible pathways:

Adipose tissue and oestrogen production: Body fat tissue is an active site of oestrogen synthesis. As weight decreases, oestrogen production from adipose tissue falls. In women who were overweight or obese, this can be a significant change in total oestrogen exposure. The hypothalamic-pituitary-ovarian axis responds to this shift, which can temporarily disrupt cycle regularity.

Rapid weight loss signal: The hypothalamus is sensitive to energy balance. Rapid weight loss, particularly if calorie intake drops significantly, can signal to the reproductive axis that nutritional conditions are unfavourable. This is a protective mechanism, not pathology, but it can manifest as cycle irregularity.

GLP-1 receptor distribution: GLP-1 receptors are expressed in the ovaries and uterus. Direct hormonal effects of semaglutide on reproductive tissue cannot be ruled out, though the clinical significance is not yet well characterised.

For most women, menstrual changes in the early months on Wegovy are temporary. Cycles tend to regularise as weight stabilises and the body adapts. However, any persistent change to your cycle, particularly heavy bleeding or missed periods beyond the first 2-3 months, should be discussed with your GP.

Fertility and Contraception

This is important: Wegovy can increase fertility in women who were previously ovulating less regularly due to conditions such as PCOS. If you are not trying to conceive, this means your existing contraception needs to remain in place and in use.

Additionally, during dose escalation, vomiting and diarrhoea may reduce the absorption of oral contraceptive pills. If you are on the pill and experiencing significant GI side effects, consider using additional contraception (barrier methods) during this period.

Wegovy is not recommended during pregnancy. If you become pregnant while on Wegovy, stop the medication and contact your GP. The medication is contraindicated in pregnancy due to animal study findings; weight loss during pregnancy is not recommended.

For women with PCOS specifically, the effects of GLP-1 treatment on cycle regularity, androgen levels, and fertility potential are covered in detail in GLP-1 for PCOS in the UK.

Hair Loss

Hair thinning typically appears 2-4 months after starting treatment. It is not caused by the medication directly; it is caused by the rapid calorie restriction that accompanies significant appetite suppression. The clinical term is telogen effluvium, and it is temporary.

The key interventions are nutritional: maintaining adequate protein intake (at least 1.4-1.6 g per kg of body weight daily), checking ferritin levels, and supporting micronutrient status. The full mechanism and management protocol are covered in GLP-1 hair loss prevention in the UK.

Less Common but Serious Side Effects

Other less common effects to be aware of:

Gallstones: Rapid weight loss increases gallstone risk, and this effect is seen with all effective weight loss treatments including GLP-1 medications. If you have right-sided upper abdominal pain, particularly after fatty meals, report this to your GP.

Heart rate: Semaglutide can increase resting heart rate by approximately 1-4 beats per minute. For most people this is not clinically significant, but it should be noted in people with pre-existing heart rate conditions.

Thyroid: Semaglutide carries a boxed warning for medullary thyroid carcinoma in people with a personal or family history of this specific thyroid cancer or MEN2 syndrome. This is why prescribers ask about your thyroid history.

Diabetic eye disease: In people with pre-existing type 2 diabetes who also have diabetic retinopathy, rapid glucose reduction can temporarily worsen retinopathy. This is a known and manageable risk with appropriate ophthalmology follow-up.

Getting Clinical Support

Side effects are much easier to manage with access to a prescriber or nurse who knows your case. One of the consistent criticisms of budget-only GLP-1 services is that support between consultations is limited, which matters most during the difficult early weeks.

If you're comparing options before starting, see the best GLP-1 clinics in the UK 2026 for a full breakdown of what each service offers in terms of support.

When to Contact Your Clinic

Contact the same day or urgently:

• Severe abdominal pain, especially radiating to the back
• Inability to keep fluids down for more than 24 hours
• Signs of dehydration: dark urine, dizziness, rapid heartbeat
• Severe constipation (no bowel movement for 5 or more days)
• Chest pain or palpitations
• Vision changes

Schedule a call within the week:

• Nausea or vomiting that is not improving after 3 weeks at a stable dose
• Significant menstrual changes that persist beyond month 2
• Weight loss that has stalled completely before reaching the therapeutic dose
• Persistent diarrhoea at a stable dose
• Symptoms of depression or significant mood changes (GLP-1s may affect mental health; see GLP-1 and mental health)

The Side Effect Timeline Summary

| Timeframe | What to Expect | |-----------|----------------| | Week 1-2 | Nausea, possible fatigue, reduced appetite. May feel rough. | | Week 3-4 | Symptoms beginning to ease. Appetite suppression becoming the main effect. | | Week 5-8 | Dose increase at week 5 may trigger renewed GI symptoms. Usually milder than the first. | | Week 9-12 | For most women, side effects have significantly reduced. | | Week 13-16 | Third dose increase. Brief adaptation period expected. | | Week 17+ | On therapeutic dose. Side effects for most women: minimal to none. | | Month 2-4 | Possible hair thinning beginning. Menstrual changes may be noticed in this window. |